Protocol for Active Surveillance Testing and Specimen Submission for Confirmed CRE

The Louisiana Public Health Laboratory (PHL) is working in collaboration with the Tennessee Antibiotic Resistance Laboratory Network (ARLN) and Centers for Disease Control and Prevention (CDC) to conduct enhanced surveillance of Carbapenem-Resistant Enterobacteriaceae (CRE) colonization screening. Through the methodology below, we will be able to screen and detect colonizing CRE among contacts in a manner that is critical to prevent transmission. By participating in this surveillance scheme, you will be able to submit isolates at no cost to your facility. This testing scheme is aimed at acute care hospitals. If facility transmission is determined, an infection control assessment and response (ICAR) review will be held in collaboration between the submitting facility and the HAI-AR Program.

CRE Case Definition

E. coli, Klebsiella spp., or Enterobacter spp. that is resistant to any carbapenem (minimum inhibitory concentrations of ≥4 mcg/ml for meropenem, imipenem, and doripenem or ≥ 2 mcg/ml for ertapenem)

OR

production of a carbapenemase (e.g., KPC, NDM, VIM, IMP, OXA-48) demonstrated by a recognized test (e.g., polymerase chain reaction, modified Hodge test (MHT), Carba NP, or metallo-β-lactamase testing (e.g., MBL E-test or other screening method). For bacteria with intrinsic imipenem non-susceptibility (i.e., Morganella morganii, Proteus spp., Providencia spp., Serratia spp.), non-susceptibility to carbapenems other than imipenem is required.

The Healthcare-Associated Infections and Antibiotic Resistance Program addresses prevention and surveillance activities related to infection control and antimicrobial threats across the provider spectrum. For more information, contact www.ldh.la.gov/HAI or call the Infectious Disease Epidemiology Section of the Louisiana Office of Public Health at 504-568-8313.

Created July 6, 2017
Updated August 20, 2017
E-mail Template for Requesting Swabs for CRE Active Surveillance Testing and Antibiotic Sensitivity

*Be sure to attach a scanned copy of hospital/reference laboratory results*

To: ARLN.Health@tn.gov  
CC: HAI@la.gov  
Subject: Urgent - CRE AST Request - (Insert Facility Name)

(Insert Facility Name) received a positive CRE on (date) from a patient housed on the (insert) unit. Will you please forward swabs and shipping information for Epi-linked patients identified on the same room/unit? Additional details are as follows:

- Patient Name
- Date of Birth
- Medical Record Number
- Address
- Date of admit
- Date of culture
- Unit where specimen was collected
- Specimen source
- Submitting Facility
- Submitting Facility Address
- Contact Name
- Contact Phone Number

<table>
<thead>
<tr>
<th>Contacts</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:Andrea.Salinas@LA.gov">Andrea.Salinas@LA.gov</a></td>
<td>HAI Epidemiologist</td>
<td>Infectious Disease Epidemiology</td>
</tr>
<tr>
<td><a href="mailto:Jean-Jacques.Aucoin@LA.gov">Jean-Jacques.Aucoin@LA.gov</a></td>
<td>Microbiology Manager</td>
<td>LA Public Health Laboratory</td>
</tr>
<tr>
<td><a href="mailto:LeAnn.Covington@LA.gov">LeAnn.Covington@LA.gov</a></td>
<td>Biosafety Officer</td>
<td>LA Public Health Laboratory</td>
</tr>
<tr>
<td><a href="mailto:ARLN.Health@TN.gov">ARLN.Health@TN.gov</a></td>
<td>Southeast Regional ARLN Laboratory</td>
<td>Tennessee Department of Health</td>
</tr>
</tbody>
</table>